Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States

By sjmartinez • February 11, 2023

Tenforde MW, Self WH, Zhu Y, Naioti EA, Gaglani M, Ginde AA, Jensen K, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Lohuis CT, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Botros MM, Lauring AS, Shapiro NI, Halasa N, Chappell JD, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Rhoads JP, Lindsell CJ, Hart KW, Turbyfill C, Olson S, Murray N, Adams K, Patel MM; Influenza and Other Viruses in the Acutely Ill (IVY) Network. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis. 2023 Feb 8;76(3):e460-e468. doi: 10.1093/cid/ciac381. PMID: 35580849; PMCID: PMC9129194.

Tags: covid-19, duration of protection, mRNA, Publications, Pulmonary, Critical Care & Sleep Medicine, vaccine effectiveness, waning

New-Onset Atrial Fibrillation as a Predictor of Cancer: Insights from a Real-World Dataset

Alzahrani A, Gokul K, Paleri A, Powers EM, Bailin S, Yang EH, Fradley M, Farjo P, Dominic P. New-Onset Atrial Fibrillation as a Predictor of[...]

The REgistry of Flow and Perfusion Imaging for Artificial Intelligence with positron emission tomography (REFINE PET):Rationale and design

Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Miller RJH, Kavanagh PB, Liang JX, Dey D, Slipczuk L, Travin MI, Alexanderson E, Carvajal-Juarez I, Packard[...]

Editorial Commentary

Lerman M, Waterman B, Bergman J. Editorial Commentary. Urol Pract. 2025 Nov;12(6):643. doi: 10.1097/UPJ.0000000000000870. Epub 2025 Oct 23. PMID: 41128384.